Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

导出 LinkOut

翻译打印收藏纠错

作者： Irene M,Ghobrial ^[1] ; Chia-Jen,Liu ^[1] ; Oksana,Zavidij ^[1] ; Abdel K,Azab ^[1] ; Rachid,Baz ^[2] ; Jacob P,Laubach ^[3] ; Yuji,Mishima ^[1] ; Philippe,Armand ^[1] ; Nikhil C,Munshi ^[1] ; Frank,Basile ^[1] ; Michael,Constantine ^[4] ; James,Vredenburgh ^[5] ; Adam,Boruchov ^[6] ; Pamela,Crilley ^[6] ; Patrick M,Henrick ^[7] ; Kalvis T V,Hornburg ^[1] ; Houry,Leblebjian ^[1] ; Stacey,Chuma ^[1] ; Kaitlen,Reyes ^[1] ; Kimberly,Noonan ^[1] ; Diane,Warren ^[1] ; Robert,Schlossman ^[1] ; Claudia,Paba-Prada ^[1] ; Kenneth C,Anderson ^[1] ; Edie,Weller ^[1] ; Lorenzo,Trippa ^[8] ; Kenneth,Shain ^[8] ; Paul G,Richardson ^[3]

作者单位： Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. ^[1] Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, St. Louis, Missouri. ^[2] Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[3] Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis, Massachusetts. ^[4] Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Milford Regional Medical Center, Milford, Massachusetts. ^[5] Department of Medical Oncology, Saint Francis Hospital and Medical Center, Hartford, Connecticut. ^[6] Department of Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, Pennsylvania. ^[7] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[8]